Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | +9.52% | 0.00% | +16.75% |
Apr. 05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
Apr. 05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
Sales 2024 * | 2.24M 2.85M | Sales 2025 * | 3.28M 4.17M | Capitalization | 7.14M 9.07M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.27M | Net income 2025 * | - 0 | EV / Sales 2024 * | 1.55 x |
Net cash position 2024 * | 3.66M 4.65M | Net cash position 2025 * | 2.95M 3.74M | EV / Sales 2025 * | 1.28 x |
P/E ratio 2024 * |
-2.65
x | P/E ratio 2025 * |
-7.67
x | Employees | 48 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.93% |
Latest transcript on RUA Life Sciences plc
1 day | +9.52% | ||
1 month | +4.55% | ||
3 months | +7.48% | ||
6 months | -47.73% | ||
Current year | +16.75% |
Managers | Title | Age | Since |
---|---|---|---|
Lachlan Smith
DFI | Director of Finance/CFO | - | 21-11-30 |
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John McKenna
BRD | Director/Board Member | 71 | 16-10-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Brown
CHM | Chairman | 55 | 11-10-20 |
John Louis Ely
BRD | Director/Board Member | 73 | - |
Director/Board Member | 57 | 21-01-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 11.5 | +9.52% | 592,973 |
24-05-17 | 10.5 | 0.00% | 142,262 |
24-05-16 | 10.5 | 0.00% | 60,354 |
24-05-15 | 10.5 | -4.55% | 232,832 |
24-05-14 | 11 | -4.35% | 116,063 |
Delayed Quote London S.E., May 20, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.75% | 8.28M | |
+11.91% | 227B | |
+15.46% | 197B | |
+18.58% | 141B | |
+30.36% | 110B | |
+0.65% | 64.15B | |
+17.74% | 53.72B | |
+5.82% | 51.75B | |
+11.23% | 45.2B | |
+5.73% | 37.37B |
- Stock Market
- Equities
- RUA Stock